Patient characteristics
| Variables . | HCMV controllers (n = 11) . | csCMVi (n = 13) . | P value∗ . |
|---|---|---|---|
| Age, median (range) | 57 (22-74) | 65 (33-77) | .17 |
| Sex, n (%) | |||
| Male | 7 (64) | 8 (62) | >.99 |
| Female | 4 (36) | 5 (38) | |
| Underlying disease, n (%) | |||
| Chronic leukemia | 0 (0) | 1 (8) | |
| Multiple myeloma | 0 (0) | 1 (8) | |
| Acute leukemia | 6 (55) | 10 (77) | - |
| Lymphoma | 1 (9) | 0 (0) | |
| Others | 4 (36) | 1 (8) | |
| HLA matching, n (%) | |||
| Matched related | 0 (0) | 5 (38) | |
| Matched unrelated | 9 (82) | 6 (46) | - |
| Haploidentical | 0 (0) | 0 (0) | |
| Mismatch | 2 (18) | 2 (15) | |
| Stem cell source, n (%) | |||
| PBSC | 11 (100) | 13 (100) | 1 |
| Conditioning regimen, n (%) | |||
| Reduced intensity | 11 (100) | 13 (100) | 1 |
| Antithymocyte globulin, n (%) | |||
| No | 0 (0) | 4 (31) | .10 |
| Yes | 11 (100) | 9 (69) | |
| HCT-CI, n (%) | |||
| 0-2 | 7 (64) | 8 (62) | - |
| 3-4 | 2 (18) | 5 (38) | |
| ≥5 | 2 (18) | 0 (0) | |
| aGvHD, n (%) | |||
| 0-1 | 10 (91) | 7 (54) | .08 |
| 2-4 | 1 (9) | 6 (46) | |
| cGvHD, n (%) | |||
| No | 10 (91) | 10 (77) | .60 |
| Yes | 1 (9) | 3 (33) | |
| Serostatus (R/D), n (%) | |||
| +/+ | 10 (91) | 8 (62) | .17 |
| +/− | 1 (9) | 5 (38) | |
| 1-year mortality, n (%) | |||
| Alive | 11 (100) | 12 (92) | >.99 |
| Dead | 0 (0) | 1 (8) |
| Variables . | HCMV controllers (n = 11) . | csCMVi (n = 13) . | P value∗ . |
|---|---|---|---|
| Age, median (range) | 57 (22-74) | 65 (33-77) | .17 |
| Sex, n (%) | |||
| Male | 7 (64) | 8 (62) | >.99 |
| Female | 4 (36) | 5 (38) | |
| Underlying disease, n (%) | |||
| Chronic leukemia | 0 (0) | 1 (8) | |
| Multiple myeloma | 0 (0) | 1 (8) | |
| Acute leukemia | 6 (55) | 10 (77) | - |
| Lymphoma | 1 (9) | 0 (0) | |
| Others | 4 (36) | 1 (8) | |
| HLA matching, n (%) | |||
| Matched related | 0 (0) | 5 (38) | |
| Matched unrelated | 9 (82) | 6 (46) | - |
| Haploidentical | 0 (0) | 0 (0) | |
| Mismatch | 2 (18) | 2 (15) | |
| Stem cell source, n (%) | |||
| PBSC | 11 (100) | 13 (100) | 1 |
| Conditioning regimen, n (%) | |||
| Reduced intensity | 11 (100) | 13 (100) | 1 |
| Antithymocyte globulin, n (%) | |||
| No | 0 (0) | 4 (31) | .10 |
| Yes | 11 (100) | 9 (69) | |
| HCT-CI, n (%) | |||
| 0-2 | 7 (64) | 8 (62) | - |
| 3-4 | 2 (18) | 5 (38) | |
| ≥5 | 2 (18) | 0 (0) | |
| aGvHD, n (%) | |||
| 0-1 | 10 (91) | 7 (54) | .08 |
| 2-4 | 1 (9) | 6 (46) | |
| cGvHD, n (%) | |||
| No | 10 (91) | 10 (77) | .60 |
| Yes | 1 (9) | 3 (33) | |
| Serostatus (R/D), n (%) | |||
| +/+ | 10 (91) | 8 (62) | .17 |
| +/− | 1 (9) | 5 (38) | |
| 1-year mortality, n (%) | |||
| Alive | 11 (100) | 12 (92) | >.99 |
| Dead | 0 (0) | 1 (8) |
Characteristics of alloSCT patients who controlled HCMV (controllers) and patients with csCMVi.
aGvHD, acute GvHD; cGvHD, chronic GvHD; csCMVi, clinically significant HCMV infection; HCT-CI, hematopoietic cell transplantation comorbidity index; PBSC, peripheral blood stem cells.
Mann-Whitney U test or Fisher's exact test was used, as appropriate.